Back to top

Alzamend Neuro’s New Lithium Study Puts AL001 in the Bipolar Disorder Spotlight

Alzamend Neuro, Inc. ($ALZN) announced an update on their ongoing clinical study. Alzamend Neuro, Inc. has launched a new study called “A Study to ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Alzamend Neuro, Inc. (ALZN)